Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report

POKRIVČÁK, Tomáš, Jiří NAVRÁTIL, Alexandr POPRACH, Michal STANÍK and Igor KISS. Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report. CASE REPORTS IN ONCOLOGY. BASEL: KARGER, 2024, vol. 17, No 1, p. 537-542. ISSN 1662-6575. Available from: https://dx.doi.org/10.1159/000538124.

Basic information

• Original name: Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
• Authors: POKRIVČÁK, Tomáš (203 Czech Republic, belonging to the institution), Jiří NAVRÁTIL (203 Czech Republic, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution), Michal STANÍK (703 Slovakia, belonging to the institution) and Igor KISS (203 Czech Republic, belonging to the institution).
• Edition: CASE REPORTS IN ONCOLOGY, BASEL, KARGER, 2024, 1662-6575.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30204 Oncology
• Country of publisher: Switzerland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 0.800 in 2022
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1159/000538124
• UT WoS: 001201754100001
• Keywords in English: Enzalutamide; Metastatic castration-resistant prostate cancer; Aged 75 and over; Comorbidity
• Tags: 14110811, rivok
• Tags: International impact, Reviewed

Abstract

Introduction: Prostate cancer is one of the most common cancers in men. Despite the sharp rise in incidence, mortality is decreasing. ARTA preparations are preferred options for asymptomatic or mildly symptomatic patients with mCRPC. The use of enzalutamide in elderly patients with mCRPC is risky and depends on a number of factors. An increased risk of falls and fractures has been shown. Case Presentation: We present a case report of an elderly patient with mCRPC treated with enzalutamide with very good long-term tolerance and efficacy. Conclusion: Despite the older age, no reduction of therapy was necessary in the patient due to good tolerance. Administration of enzalutamide in full doses resulted in a very good effect of therapy.